Second Genome Appoints Karim Dabbagh, Ph.D., as Chief Scientific Officer
September 9, 2014, South San Francisco, CASecond Genome, Inc., a leader in the development of novel medicines through innovative microbiome science, announced today that it has appointed Karim Dabbagh, Ph.D., as the company’s Chief Scientific Officer. In this new position, Dr. Dabbagh will be responsible for the company’s drug pipeline, fueled by Second Genome’s novel discovery platform for identifying and validating microbiome-mediated drug targets and therapeutics.
Second Genome Enters Into Agreement with Pfizer Inc. on Microbiome Research Initiative in Obesity
May 2, 2014, South San Francisco, CASecond Genome announced today that it has entered into an agreement with Pfizer Inc. to conduct extensive microbiome research in a large observational study aimed at gaining new insights into obesity and metabolic disease. The goal of the study is to evaluate numerous clinical factors and the microbiome in a select cohort of approximately 900 individuals with varying metabolic phenotypes, in order to better understand the inter-relationship between the microbiome, obesity and metabolic disorders.
Second Genome Announces Agreement with Janssen on Microbiome Drug Discovery in Ulcerative Colitis
June 5, 2013, San Bruno, CASecond Genome, Inc. announced today that the company has entered into an agreement with Janssen Biotech, Inc. (Janssen) focused on microbiome drug discovery. With the goal of advancing novel drug targets, the agreement is focused on therapeutic mechanisms in ulcerative colitis mediated by the bacterial ecosystem living within the human gut, referred to as the microbiome. Second Genome will apply its microbiome modulation discovery platform to characterize the role of bacterial populations in ulcerative colitis.
Second Genome Sponsors American Gut Initiative to Identify Links Between Type 2 Diabetes and the Human Microbiome
January 3, 2013, San Francisco, CASecond Genome announced today an initiative with the American Gut project to explore the connection between the human microbiome and type 2 diabetes. The cooperation will bring together American Gut's broad citizen science network for microbiome sample collection with Second Genome's efforts in identifying microbiome modulators and novel therapeutics. Second Genome has made an undisclosed donation to American Gut to subsidize specimen collection for participants with type 2 diabetes.
Second Genome Presents Preclinical Research on the Impact of the Microbiome on C. difficile Infection
November 2, 2012, San Bruno, CASecond Genome announced today new research demonstrating the impact that commensal or healthy bacteria have on the ability of the gut microbiome, the diverse population of microbes that inhabit the intestinal flora, to prevent against C. difficile infection. Preclinical data demonstrated a correlation between time from disruption to restoration of the microbiome and the ability for C. difficile to grow. These findings suggest that promotion of growth and rehabilitation of the gut microbiome may help close the window of susceptibility to C. difficileinfection.
Second Genome Announces Human Microbiome Project Publications
June 13, 2012, San Bruno, CASecond Genome is pleased to highlight co-authorship by Todd DeSantis, Second Genome co-founder and Director of Bioinformatics, on Structure, Function and Diversity of the Healthy Human Microbiome and A Framework for Human Microbiome Research, part of a collection of papers from the Human Microbiome Project (HMP) to be published in the June 14th issue of the journal Nature.
Second Genome Announces Expansion of Scientific Advisory Board
March 31, 2012, San Bruno, CASecond Genome today announced the expansion of our Scientific Advisory Board. Our preeminent board of leaders in the genomic technologies and microbiome space now includes: Dr. Gary Andersen, Dr. Martin Blaser, Dr. Michael Fischbach, Dr. Susan Lynch, Dr. Pankaj Jay Pasricha, Dr. David Relman, and Dr. Justin Sonnenburg.
Second Genome Announces New SVP of Corporate Development
November 30, 2011, San Bruno, CASecond Genome welcomes Mohan S. Iyer to the team. As SVP of Corporate Development, Mohan is responsible for building relationships and working with our partners, including biopharma and nutrition companies, to identify novel biomarkers for classifying patient populations and to assess the impact of novel microbiome-modulating products.